P42336 (PK3CA_HUMAN) Homo sapiens (Human)

Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform UniProtKBInterProSTRINGInteractive Modelling

1068 aa; Sequence (Fasta) Identical sequences: Pan troglodytes: K7BQ68; Gorilla gorilla gorilla: G3R1S6; Mandrillus leucophaeus: A0A2K5YVM5; Papio anubis: A0A096MY63; Macaca nemestrina: A0A2K6C9I6; Macaca mulatta: H9FVU5; Macaca fascicularis: G7NZ32; Chlorocebus sabaeus: A0A0D9RKI4; Colobus angolensis palliatus: A0A2K5IJ73

Sequence Features

 38R -> H (in CRC; likely involved in disease pathogenesis; shows an increase in lipid kinase activity; may disrupt the interaction between the PI3K-ABD domain and the N-terminal lobe of PI3K/PI4K kinase domain possibly affecting the conformation of the kinase domain; dbSNP:rs772110575). VAR_026166 dbSNP
 43I -> V (in dbSNP:rs1051399). VAR_042942 dbSNP
 81E -> K (in MCAP; dbSNP:rs1057519929). VAR_069251 dbSNP
 88R -> Q (in MCAP; also found in a glioblastoma multiforme sample; dbSNP:rs121913287). VAR_026167 dbSNP
 106G -> V (in CRC; likely involved in disease pathogenesis; shows an increase in lipid kinase activity; dbSNP:rs1057519930). VAR_026168 dbSNP
 112I -> N (in MCAP; increased phosphatidylinositol 3-kinase signaling; decreased interaction with p85 regulatory subunit; no effect on protein abundance; dbSNP:rs863225460). VAR_075634 dbSNP
 118G -> D (in CWS5; dbSNP:rs587777790). VAR_069786 dbSNP
 135E -> K (in CWS5; dbSNP:rs587777791). VAR_069787 dbSNP
 218E -> K (in CWS5; dbSNP:rs587777792). VAR_069788 dbSNP
 332S -> R (in dbSNP:rs1051407). VAR_042943 dbSNP
 343Y -> C (found in a cancer sample; unknown pathological significance). VAR_026169
 356V -> I (in CWS5; dbSNP:rs587777793). VAR_069789 dbSNP
 364G -> R (in MCAP). VAR_069252
 365E -> K (in MCAP; dbSNP:rs1064793732). VAR_069253 dbSNP
 378C -> Y (in MCAP; dbSNP:rs397514565). VAR_069254 dbSNP
 382R -> K (in CWS5; dbSNP:rs587777794). VAR_069790 dbSNP
 391I -> M (in dbSNP:rs2230461). VAR_026170 dbSNP
 420C -> R (in CLOVE and CRC; shows an increase in lipid kinase activity; may increase the affinity for lipid membranes; dbSNP:rs121913272). VAR_026171 dbSNP
 453E -> Q (in CRC; likely involved in disease pathogenesis; shows an increase in lipid kinase activity; may disrupt the interaction of the C2 PI3K-type domain with the iSH2 region of the p85 regulatory subunit; dbSNP:rs1057519925). VAR_026172 dbSNP
 453Missing (in MCAP). VAR_069255
 542E -> K (in CLOVE, KERSEB, CRC and BC; also found in glioblastoma multiforme and endometrial carcinoma; shows an increase in lipid kinase activity; oncogenic in vivo; occurs in the interface between the PI3K helical domain and the nSH2 (N- terminal SH2) region of the p85 regulatory subunit and may reduce the inhibitory effect of p85; requires interaction with RAS to induce cellular transformation; dbSNP:rs121913273). VAR_026173 dbSNP
 542E -> Q (found in an endometrial carcinoma sample; unknown pathological significance; dbSNP:rs121913273). VAR_026174 dbSNP
 542E -> V (in BC; unknown pathological significance; dbSNP:rs1057519927). VAR_026175 dbSNP
 545E -> A (in CWS5 and HCC; also found in a glioblastoma multiforme sample; dbSNP:rs121913274). VAR_026176 dbSNP
 545E -> G (in KERSEB; also found in an endometrial carcinoma sample; dbSNP:rs121913274). VAR_026177 dbSNP
 545E -> K (in MCAP, KERSEB, CRC and BC; shows an increase in lipid kinase activity; oncogenic in vivo; occurs in the interface between the PI3K helical domain and the nSH2 (N-terminal SH2) region of the p85 regulatory subunit and may reduce the inhibitory effect of p85; requires interaction with RAS to induce cellular transformation; enhances invadopodia-mediated extracellular matrix degradation and invasion in breast cancer cells; dbSNP:rs104886003). VAR_026178 dbSNP
 546Q -> E (in BC; unknown pathological significance; dbSNP:rs121913286). VAR_026179 dbSNP
 546Q -> K (in OC; unknown pathological significance; dbSNP:rs121913286). VAR_026180 dbSNP
 546Q -> P (found in an anaplastic astrocytoma sample; unknown pathological significance; dbSNP:rs397517201). VAR_026181 dbSNP
 546Q -> R (in BC; unknown pathological significance; dbSNP:rs397517201). VAR_026182 dbSNP
 726E -> K (in MCAP; dbSNP:rs867262025). VAR_069256 dbSNP
 914G -> R (in MCAP; dbSNP:rs587776932). VAR_069257 dbSNP
 1007G -> R (found in an endometrial carcinoma sample; unknown pathological significance). VAR_026183
 1021Y -> C (in MCAP; also found in an endometrial carcinoma sample; dbSNP:rs121913288). VAR_026184 dbSNP
 1021Y -> H (found in an endometrial carcinoma sample; unknown pathological significance). VAR_026185
 1021Y -> N (found in a glioblastoma multiforme sample; unknown pathological significance). VAR_026186
 1023R -> Q (in CRC; unknown pathological significance). VAR_026187
 1025T -> A (in MCAP; dbSNP:rs397517202). VAR_069258 dbSNP
 1025T -> N (found in a glioblastoma multiforme sample; unknown pathological significance). VAR_026188
 1035A -> V (in MCAP; also found in an endometrial carcinoma sample; dbSNP:rs1242945375). VAR_026189 dbSNP
 1043M -> I (in MCAP and CRC; also found in an endometrial carcinoma sample; shows an increase in lipid kinase activity; dbSNP:rs121913283). VAR_026190 dbSNP
 1047H -> L (in BC; unknown pathological significance; dbSNP:rs121913279). VAR_026191 dbSNP
 1047H -> R (in CLOVE, KERSEB, CRC, BC and OC; also found in an endometrial carcinoma sample; shows an increase in lipid kinase activity; oncogenic in vivo; requires binding to p85 regulatory subunit to induce cellular transformation but not interaction with RAS; may mimic the conformatitonal change triggered by the interaction with RAS; enhances invadopodia-mediated extracellular matrix degradation and invasion in breast cancer cells; increases lipid kinase activity; may alter the interaction of the PI3K/ PI4K kinase domain with the cell membrane; dbSNP:rs121913279). VAR_026192 dbSNP
 1047H -> Y (in MCAP; also found in an endometrial carcinoma sample; dbSNP:rs121913281). VAR_026193 dbSNP
 1049G -> S (in MCAP; dbSNP:rs121913277). VAR_069259 dbSNP
 1050G -> D (found in an endometrial carcinoma sample; unknown pathological significance). VAR_026194
 1052T -> K (found in an endometrial carcinoma sample; unknown pathological significance). VAR_026195
 1065H -> L (found in an endometrial carcinoma sample; unknown pathological significance). VAR_026196
 1065H -> Y (found in brain tumors; unknown pathological significance). VAR_026197
 32-107Phosphatidylinositol 3-kinase adaptor-bi nding (PI3K ABD) domain
IPR003113PF02192
 174-291Phosphatidylinositol 3-kinase Ras-bindin g (PI3K RBD) domain
IPR000341PF00794
 351-483Phosphatidylinositol 3-kinase, C2 domain
IPR002420PF00792
 521-703Phosphoinositide 3-kinase, accessory (PI K) domain
IPR001263PF00613
 798-1014Phosphatidylinositol 3-/4-kinase, cataly tic domain
IPR000403PF00454

Sequence Alignments

Experimental structures

DescriptionOligo-stateLigandsStructureRangeDownloadAssess
'Discovery of imidazo[1,2-a]-pyridine inhibitors of pan-PI3 kinases that are efficacious in a mou... Heteromer
P27986;
5XV;GOL;5fi42-1062
p110alpha/p85alpha with compound 5 Heteromer
P23727;
5H2;5dxh2-1062
Co-crystal Structures of the Lipid Kinase PI3K alpha with Pan and Isoform Selective Inhibitors Heteromer
P27986;
1LT;SCN;4jps2-1061
Crystal Structure of a novel tetrahydropyrazolo[1,5-a]pyrazine in an engineered PI3K alpha Heteromer
P27986;
3K6;4waf2-1061
'Co-crystal Structure of Lipid Kinase PI3K alpha with a selective phosphatidylinositol-3 kinase a... Heteromer
P27986;
4Q2;4zop2-1061
'Crystal structure of p110alpha H1047R mutant in complex with niSH2 of p85alpha and the drug wort... Heteromer
P27986;
KWT;3hhm5-1062
Crystal structure of PI3K alpha with PI3K delta inhibitor Heteromer
P27986;
6CY;5itd2-1059
Crystal structure of p110alpha H1047R mutant in complex with niSH2 of p85alpha Heteromer
P27986;
3hiz5-1062
The co-structure of (R)-4-(6-(1-(cyclopropylsulfonyl)cyclopropyl)-2-(1H-indol-4-yl)pyrimidin-4-yl... Heteromer
P27986;
8DV;5uk82-1057
Crystal Structure of PI3Kalpha in complex with fragment 23 Heteromer
P27986;
SOA;5sxb1-1056
Structure of p110alpha/niSH2 - vector data collection Heteromer
P27986;
144;SO4;6nct2-1057
Crystal Structure of PI3Kalpha in complex with fragment 10 Heteromer
P27986;
71N;5sxa3-1058
Crystal Structure of PI3Kalpha in complex with fragments 6 and 24 Heteromer
P27986;
70V;70W;CL;5swp1-1054
Crystal Structure of PI3Kalpha in complex with fragments 17 and 27 Heteromer
P27986;
71B;71A;5swt1-1054
Crystal Structure of PI3Kalpha in complex with fragment 22 Heteromer
P27986;
71F;5sxd1-1054
Crystal Structure of PI3Kalpha in complex with fragments 19 and 28 Heteromer
P27986;
71G;ES3;5sxe1-1054
Crystal structure of PI3Kalpha in complex with fragments 7 and 11 Heteromer
P27986;
FB1;EPE;70S;5sw81-1053
Crystal Structure of PI3Kalpha in complex with fragments 12 and 15 Heteromer
P27986;
71M;LUZ;5sx82-1054
Crystal Structure of PI3Kalpha in complex with fragment 14 Heteromer
P27986;
71L;5sx91-1053
Crystal Structure of p110alpha complexed with niSH2 of p85alpha and PI-103 Heteromer
P27986;
GOL;X6K;SO4;4l238-1059
Crystal structure of PI3K complex with an inhibitor Heteromer
P27986;
GOL;84R;P6G;SO4;5xgi8-1059
The co-structure of N,N-dimethyl-4-[(6R)-6-methyl-5-(1H-pyrrolo[2,3- b]pyridin-4-yl)-4,5,6,7-tetr... Heteromer
P27986;
3K6;5ukj2-1053
The co-structure of 3-amino-6-(4-((1-(dimethylamino)propan-2-yl)sulfonyl)phenyl)-N-phenylpyrazine... Heteromer
P27986;
8DY;5ul12-1053
Crystal Structure of PI3Kalpha in complex with fragments 5 and 21 Heteromer
P27986;
CAQ;AX7;5swg1-1052
Crystal Structure of PI3Kalpha in complex with fragments 20 and 26 Heteromer
P27986;
SAL;CL;718;5swr1-1052
Crystal Structure of PI3Kalpha in complex with fragment 13 Heteromer
P27986;
71J;5sxi5-1056
Crystal Structure of PI3Kalpha in complex with fragments 4 and 19 Heteromer
P27986;
70T;2ZV;CL;5swo1-1052
Crystal Structure of PI3Kalpha in complex with fragment 18 Heteromer
P27986;
71K;5sxk1-1052
Crystal Structure of p110alpha complexed with niSH2 of p85alpha Heteromer
P27986;
SO4;4l1b8-1058
Crystal Structure of PI3Kalpha in complex with fragment 8 Heteromer
P27986;
URF;5sxc2-1052
Crystal Structure of PI3Kalpha in complex with diC4-PIP2 Heteromer
P27986;
PBU;PO4;4ovv4-1053
Crystal Structure of PI3Kalpha in complex with fragment 29 Heteromer
P27986;
BHO;5sxj3-1051
Crystal structure of PI3K complex with an inhibitor Heteromer
P27986;
GOL;84U;SO4;5xgh8-1055
Crystal structure of PI3K complex with an inhibitor Heteromer
P27986;
SO4;84X;5xgj8-1055
Crystal Structure of PI3Kalpha in complex with fragment 9 Heteromer
P27986;
HPP;5sxf4-1051
Crystal Structure of p110alpha in complex with niSH2 of p85alpha Heteromer
P27986;
4ovu6-1052
Crystal Structure of p110alpha complexed with niSH2 of p85alpha and compound 9d Heteromer
P27986;
XXK;GOL;SO4;4l2y8-1053
Structure of a human p110alpha/p85alpha complex Heteromer
P27986;
2rd08-1050
Pi3K alpha lipid kinase with Active Site Inhibitormonomer 4EL;4ykn2-1052
p110alpha with GDC-0326monomer 5H5;EDO;5dxt107-1051
'CRYSTAL STRUCTURE OF PI3K ALPHA IN COMPLEX WITH A 7-(3-(PIPERAZIN-1-YL)PHENYL)PYRROLO[2,1-F][1,2...monomer 85S;5ubr107-1050
Isolated p110a subunit of PI3Ka provides a platform for structure-based drug designmonomer 4tuu107-1046
Isolated p110a subunit of PI3Ka provides a platform for structure-based drug designmonomer ML9;4tv3107-1046
'Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3K...monomer KKR;3zim107-1046
Solution structure of the C2 domain from human PI3-kinase p110 subunit alphamonomer 2enq331-481